Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas

Dumont, Maëlle; Ram‐Wolff, Caroline; Roelens, Marie; Brice, Pauline; Latour, Régis Peffault de; Battistella, Maxime; Madelaine, Isabelle; Delyon, Julie; Herms, F.; Bouaziz, Jean‐David; Lebbe, Célèste; Bagot, M.; Masson, Adèle de

doi:10.1111/bjd.18215

Cited by 16 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interesting results have been recently reported on the effectiveness of BV before but also after allo-HSCT in the management of transformed MF [ 30 ]. In a French retrospective cohort of nine patients, BV plus bendamustine allowed subsequent allo-HSCT in two patients with transformed SS [ 31 ]. Thus, BV may be a good option, alone or in combination, as a bridge therapy for allo-HSCT in CTCL with poor prognosis.…”

Section: Bridging Therapies To Allo-hsctmentioning

confidence: 99%

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Dumont

Latour

Ram‐Wolff

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that develop primarily in the skin. They account for almost 80% of primary cutaneous lymphomas. Epidermotropic CTCLs (mycosis fungoides (MF) and Sézary syndrome (SS)) are the most common form of CTCL. The course of the disease ranges from an indolent clinical behavior in early-stage disease to an aggressive evolution in the advanced stages. Advanced-stage disease is defined by the presence of tumors, erythroderma, or significant blood, nodal or visceral involvement. Advanced-stage disease is characterized by frequent disease relapses, refractory disease, a severely impaired quality of life and reduced overall survival. In the last twenty-five years, allogeneic hematopoietic stem cell transplantation (HSCT) has led to prolonged remissions in advanced CTCL, presumably linked to a graft-versus-lymphoma effect and is thus emerging as a potential cure of the disease. However, the high post-transplant relapse rate and severe morbidity and mortality associated with graft-versus-host disease and infections are important issues. Allogeneic HSCT is thus mostly considered in young patients with no comorbidities and an aggressive, advanced-stage CTCL. Allogeneic HSCT gives the best results in patients with a pre-transplant complete remission of the lymphoma. For this reason, one of the challenges is to define the best time to consider allogeneic HSCT in the disease course. Early identification of patients at high risk for progression is important to identify candidates who may benefit from allogeneic HSCT before their disease becomes treatment-refractory. This review describes the role of allogeneic HSCT in CTCL, summarizes the published data and future perspectives in this area.

show abstract

Section: Bridging Therapies To Allo-hsctmentioning

confidence: 99%

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Dumont

Latour

Ram‐Wolff

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 To date, studies on the risk of keratinocyte carcinoma (KC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), among patients with HS have been limited. [2][3][4][5] We performed a case-control study comparing the incidence of BCC and SCC between patients with HS…”

Section: Correspondencementioning

confidence: 99%

“…Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas DOI: 10.1111/bjd.19220 DEAR EDITOR, Prolonged complete remissions (CRs) are rare in advanced-stage cutaneous T-cell lymphomas (CTCLs). [1][2][3][4] Ifosfamide + etoposide (I+E) have been used to treat lymphomas, combined with platinum-based agents in Hodgkin disease or non-Hodgkin lymphomas including peripheral T-cell lymphomas. Monoclonal antibodies have induced long-term remissions in CTCL but are usually poorly effective in transformed disease.…”

mentioning

confidence: 99%

Ifosfamide and etoposide in advanced‐stage, relapsed or refractory primary cutaneous T‐cell lymphomas

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…While the encouraging efficacy of bendamustine and BV has been shown in Hodgkin lymphoma, and BV in combination with other chemotherapy agents has already been proven effective and safe in the frontline treatment of CD30 positive PTCL, only very limited data exist for the treatment of PTCL with bendamustine and BV. Dumont et al recently reported of nine patients with advanced PTCL that were treated with bendamustine and BV outside of prospective clinical trials, two of which achieved a CR. Although the study of O'Connor et al also included patients with PTCL, only one patient with anaplastic large T‐cell lymphoma was included in it and subsequently treated with bendamustine and BV.…”

Section: Introductionmentioning

confidence: 99%

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

Wagner

Melchardt

Egle

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objectives A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lymphoma (cHL). In this retrospective analysis, we aimed to assess this therapy's efficacy in unselected patients with cHL and CD30+ peripheral T‐cell lymphoma (PTCL). Patients and methods Data of 28 patients with cHL and five patients with PTCL treated with a combination of bendamustine and BV at three Austrian tertiary cancer centers were analyzed. Results In patients with cHL, the ORR was 100% (78.6% CR, 21.4% PR). After 17 months median follow‐up, median survival times were not reached; 1‐year PFS was 81.9%, and 1‐year OS was 95.7%. Thirteen eligible patients (46.4%) successfully underwent planned ASCT after salvage therapy with bendamustine and BV and subsequent high‐dose chemotherapy. Three of the five PTCL patients achieved CR, while two did not respond and died during or shortly after therapy. Conclusion A combination of bendamustine and BV is an effective salvage and induction therapy before ASCT in patients with relapsed/refractory cHL. Further research is warranted to evaluate the use in patients with PTCL.

show abstract

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas

Cited by 16 publications

References 8 publications

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Ifosfamide and etoposide in advanced‐stage, relapsed or refractory primary cutaneous T‐cell lymphomas

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

Contact Info

Product

Resources

About